TMCnet - World's Largest Communications and Technology Community



Research and Markets: Global Diabetic Retinopathy Market 2014-2018
[July 04, 2014]

Research and Markets: Global Diabetic Retinopathy Market 2014-2018

DUBLIN --(Business Wire)--

Research and Markets ( has announced the addition of the "Global Diabetic Retinopathy Market 2014-2018" report to their offering.

DR is defined as an eye disorder that damages the blood vessels of the retina. The retina is the light-sensitive inner surface of the eye which acts as a film for the formation of an image. Long-term diabetes affects the retina as a high blood glucose level can deteriorate and damage the tiny blood vessels in the retina.

DR is broadly classified into either non-proliferative DR or proliferative retinopathy. Treatment for DR is dependent on the stage of the disease and is directed at trying to slow or stop the progression of the disease. At present, three types of treatment exist for DR: laser surgery, injection of corticosteroids or anti-VEGF drugs into the eye, and vitrectomy.

The aalysts forecast the Global DR market will grow at a CAGR of 6.8 percent over the period 2013-2018.

Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Pipeline Snapshot

08. Rate of Incidence and Prevalence

09. Geographical Segmentation

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Trends and their Impact

17. Vendor Landscape

18. Key Vendor Analysis

19. Other Reports in this Series

Companies Mentioned:

  • Abbott Laboratories Ltd.
  • Alcon Laboratories Inc.
  • Alimera Sciences Inc.
  • Allergan Inc.
  • Ampio Pharmaceuticals Inc.
  • Antisense Therapeutics Ltd.
  • BCN (News - Alert) Peptides SA
  • Bausch & Lomb Inc.
  • Bayer AG
  • Boehringer Ingelheim GmbH
  • F. Hoffmann-La Roche Ltd.
  • Ferrosan Holding A/S
  • Isis Pharmaceuticals Inc.
  • LPath Inc.
  • Lupin Ltd.
  • Novartis AG
  • Novast Laboratories Ltd.
  • OPKO Health Inc.
  • Parexel International Corp.
  • Pfizer Inc.
  • Quark Pharmaceuticals Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sirnaomics Inc.
  • Thrombogenics NV
  • Torrent Pharmaceuticals Ltd.
  • Valeant Pharmaceuticals International Inc.
  • Vitreoretinal Technologies Inc.
  • iCo Therapeutics Inc.
  • pSivida Corp.

For more information visit

[ Back To's Homepage ]

Technology Marketing Corporation

35 Nutmeg Drive Suite 340, Trumbull, Connecticut 06611 USA
Ph: 800-243-6002, 203-852-6800
Fx: 203-866-3326

General comments:
Comments about this site:


© 2018 Technology Marketing Corporation. All rights reserved | Privacy Policy